SUVmax、Ki-67、p53、EGFR对三阴性乳腺癌新辅助化疗疗效的预测价值
DOI: 10.3971/j.issn.1000-8578.2016.01.010
Keywords: PET-CT,三阴性乳腺癌,新辅助化疗,最大标准摄取值,Ki-67,p53,EGFR,病理完全缓解（pCR）,Effect of Neoadjuvant Chemotherapy Cycles on Pathologic Complete Response Rate Under Different Estrogen Receptor Status of Breast Cancer,Effect of SAHA on Proliferation and Apoptosis of Breast Cancer Cells MDA-MB-435 and Related Mechanism,Analysis E-cad and VEGF Expression in Triple-negative Breast Cancer of Han and Uygur,Correlation of CD68+ Tumor-associated Macrophages Number with Ki-67 Expression and Prognosis of Patients with Primary Hepatocellular Carcinoma,Predictive Factors for Customizing Chemotherapy on Advanced Lung Adenocarcinoma,Effect of Long Non-coding RNA LOC100294362 on Proliferation and Invasion of Breast Cancer Cells,Research Advances of ASPP in Regulating Apoptosis of Tumor Cells,Correlation Between Epithelial-mesenchymal Transition and Sensitivity to EGFR Targeted Monoclonal Antibody in Triple Negative Breast Cancer Cells,Effect of siRNA-mediated notch1 Gene Silencing on Apoptosis and Radiosensitivity of Glioma Cell Line U87-EGFRvⅢ,Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer,Establishment of DDP Resistant Variant of Triple Negative Breast Cancer Cell Line MDA-MB-231/DDP and Its Appraisal,Killing Effect of Paclitaxel and Cisplatin on EGFR-wild and Mutant Lung Adenocarcinoma Cells and Related Molecular Mechanism,Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma,Clinical Efficacy and Toxicities of Oxaliplatin plus S-1(SOX) and Gemcitabine plus Cisplatin (GP) Regimens on Advanced Triple-negative Breast Cancer Patients,Relationship Between FoxQ1 and Epidermal Growth Factor Receptor Gene Expression in Colorectal Cancer
Abstract:
摘要 目的 探讨18F-FDG PET/CT化疗前SUVmax、Ki-67、p53、EGFR对三阴性乳腺癌（TNBC）及非三阴性乳腺癌（非TNBC）对新辅助化疗完全病理缓解（pathologic complete response, pCR）率的预测价值。方法 初治TNBC患者27例，非TNBC患者184例，在新辅助化疗前行18F-FDG PET/CT显像并测量其SUVmax，取化疗前乳腺肿瘤组织进行Ki-67、p53、EGFR免疫组织化学分析并计算化疗后完全pCR率。结果 TNBC新辅助化疗前的SUVmax明显高于非TNBC的SUVmax（P=0.045），TNBC新辅助化疗后pCR率明显高于非TNBC（P＜0.001）。在TNBC以及非TNBC中，达到pCR组的化疗前SUVmax与未达到pCR组之间差异无统计学意义（P＞0.05）。Ki-67、p53、EGFR阳性表达组的pCR率与阴性表达组之间差异无统计学意义（P＞0.05）。结论 TNBC对新辅助化疗的敏感度高于非TNBC，且TNBC化疗前SUVmax高于非TNBC，提示TNBC具有较高的能量代谢。化疗前SUVmax以及Ki-67、p53、EGFR不能预测TNBC及非TNBC新辅助化疗的pCR
Full-Text
